Abstract:
administration of anti-estrogen drugs successfully suppressed tumor growth. However respond to anti-estrogen therapy, evolution of resistance with treatment failure and 69 tumor progression typically is observed within a few months to a few years [7] .
There are three major drawbacks in anti-estrogen treatment: (1) cost and side 71 effects reduce compliance in up to 25% of the patients [8] ; (2) about 10% will develop 72 one or more side-effects that require dose adjustments or treatment cessation [1, 7, 9] 
93
A number of questions regarding optimal evolution-based treatments remain.
94
Among these, perhaps the most urgent is the apparently conflicting demands for 95 treatment in which a patient presents with highly symptomatic or potentially life-96 threatening conditions. Here, rapid and significant reduction of the tumor burden is 97 clinically necessary but could also result in competitive release of resistant clones that 98 result in rapid proliferation leading to tumor failure and tumor progression with recurrent 99 symptoms. Here we examine potential treatment strategies that can both rapidly 100 diminish tumor burden to very low levels while maintaining evolutionary dynamics that 101 can prolong tumor control and reduce the cumulative drug dose to reduce toxicity and 102 cost.
103
A second question in this study is the cost of resistance to hormonal therapy. pathways that permit estrogen-independent survival and proliferation. However, unlike 108 the dynamics of PgP, the evolutionary cost of estrogen-independence is not obvious.
109
Nevertheless, that such a cost exists can be inferred using a concept termed 110 "evolutionary triage." Briefly, "evolutionary triage" [15] 
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In-vivo Experiments
Results
220
This project was designed to understand the evolutionary dynamics of resistance 
227
In the first cohort of mice (n = 10) bearing orthotopic MCF7 tumors, Tamoxifen injections.
242
In a second cohort (n=14) we used higher concentration of Tamoxifen (50 mg/ml) 243 with 20 µl of the suspension injected i.p. daily. This reduced the peritoneal fluid 244 collection and showed the same outcome as the prior cohort ( Figure 1B) .
245
Histological analysis of ER expression showed no significant difference between the 246 intermittent and standard tamoxifen therapies ( Figure 2B) . However, the vascularity 247 (density and functionality) was decreased in TamVac therapy (Figure 3 , columns A and 248 B). MDR1 was expressed in the Tamoxifen therapy groups suggesting membrane 249 extrusion play a significant role in evolution of resistance in this setting ( Figure 4B ).
250
Finally, because the ip injection of Tamoxifen was associated with peritoneal lipid 251 collections, we examined an additional cohort of mice (n=41) in which Tamoxifen was 252 administered by gavage (no significant difference was found between ip and gavage 253 treatments, Sup. Figure 1) . This cohort included prior treatment (continuous Tamoxifen dosing and one-week vacation period) but also examined longer "vacation" periods 255 during which treatment was suspended for 2 or 3 weeks (Tam2weeks and Tam3weeks).
256
We also examined alternative sequences with Tamoxifen first followed by Paclitaxel or 257 vice-versa (TamPac and PacTam, respectively).
258
After 130 days of treatment, no significant differences in tumor control were 259 noted in the groups ( Figure 1C) . However, TamVac, Tam2weeks, and Tam3weeks Figure 3 ) when compared to the other cohorts.
268
We studied the expression of MDR1 systems for cohorts B and C using 269 immunohistochemistry (IHC) (Figure 4) . In general, cohorts with vacation periods 270 showed lower expression of MDR1 than the continuous Tamoxifen group (Figure 4 , B
271
and C) reflecting the diminished selection pressure for resistance during treatment 272 vacation.
273
We analyzed the homogeneity in the ER expression in the treatment cohorts 274 using a "neighborhood" imaging analysis, which examined variations in ER expression 275 in physically adjacent cell groups. To do so, we created a mask for the tumor slices 
